Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Malaria · Pharmacokinetics · CNSP

CNS Pharmaceuticals

CNS Pharmaceuticals clinical programs — 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Houston, TX 77027, US HQ
2017 Founded
12 Employees
Public company Type
CNSP · NYSE Ticker
Company details
Status
Public
HQ
Houston, TX 77027, US
Founded
2017
Employees
12
Programs
21
Drugs
18
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

CNS Pharmaceuticals projects

21 ClinicalTrials.gov programs sponsored by CNS Pharmaceuticals.

CNS Pharmaceuticals has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

21 programs

Clinical programs

  1. Transcranial Magnetic stimulation

    CNS Pharmaceuticals

    Gambling Disorder

    phase 3 other active

    1 trial

  2. 9941

    CNS Pharmaceuticals

    Menopause

    phase 2 small molecule terminated

    1 trial

  3. Berubicin

    CNS Pharmaceuticals

    Glioblastoma Multiforme, Adult

    phase 2 small molecule active

    1 trial

  4. Berubicin hydrochloride, Cecenu® 40 mg Kapsel

    CNS Pharmaceuticals

    Glioblastoma multiforme (GBM)

    phase 2 small molecule active

    1 trial

  5. CTX-4430

    CNS Pharmaceuticals

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  6. DSM265

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule terminated

    2 trials

  7. MMV390048 40mg

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  8. OZ439

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  9. Paclitaxel

    CNS Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  10. Sertraline+Antibiotic (penicillin/azithromycin)

    CNS Pharmaceuticals

    Pandas

    phase 2 small molecule terminated

    1 trial

  11. rTMS (repetitive transcranial magnetic stimulation)

    CNS Pharmaceuticals

    Obsessive-Compulsive Disorder

    phase 2 other active

    1 trial

  12. vitamin C

    CNS Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  13. (+)-SJ000557733

    CNS Pharmaceuticals

    Plasmodium Falciparum Malaria

    phase 1 small molecule completed

    1 trial

  14. 480 mg Piperaquine phosphate

    CNS Pharmaceuticals

    Malaria

    phase 1 small molecule completed

    1 trial

  15. ALPN-101

    CNS Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. Administration of the malaria inoculum

    CNS Pharmaceuticals

    Malaria

    phase 1 mab completed

    1 trial

  17. DAB

    CNS Pharmaceuticals

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  18. Intravenous Vitamin C

    CNS Pharmaceuticals

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  19. MMV390048 40 mg

    CNS Pharmaceuticals

    Malaria

    phase 1 small molecule completed

    1 trial

  20. PRA

    CNS Pharmaceuticals

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  21. SPR206

    CNS Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does CNS Pharmaceuticals have?

21 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.